Scinai Immunotherapeutics Ltd. (SCNI)
| Market Cap | 513.88K -88.2% |
| Revenue (ttm) | 1.49M +29.6% |
| Net Income | -2.60M |
| EPS | -4.89 |
| Shares Out | 570.02K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 379,078 |
| Open | 0.7862 |
| Previous Close | 0.8800 |
| Day's Range | 0.7600 - 0.9430 |
| 52-Week Range | 0.7500 - 15.6500 |
| Beta | 2.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 24, 2026 |
About SCNI
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical metho... [Read more]
Financial Performance
Financial StatementsNews
Scinai Immunotherapeutics announces $4M private placement
Scinai Immunotherapeutics (SCNI) announced that it has entered into a securities purchase agreement with an existing life sciences institutional investor for the purchase and sale of 2,458,334 America...
Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufact...
Scinai signs $5.1M development and clinical manufacturing agreement
Scinai Immunotherapeutics (SCNI)’ wholly owned subsidiary Scinai Biopharma Services has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biop...
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports deve...
Scinai Immunotherapeutics regains Nasdaq compliance
Scinai Immunotherapeutics (SCNI) announced that it has received written notification from Nasdaq Listing Qualifications confirming that the company has regained compliance with the $1.00 minimum bid p...
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRN...
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding ...
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd – ADR trading halted, news pending
19:50 EDT Scinai Immunotherapeutics (SCNI) Ltd – ADR trading halted, news pending
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a rev...
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immun...
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced t...
Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today?
Scinai Immunotherapeutics stock was on the rise after the company announced a $2.61 million private placement.
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
Scinai Immunotherapeutics Ltd – ADR (NASDAQ:SCNI) shares are surging Friday morning after the company announced fresh financing tied to a private placement and warrant exercise, helping refocus attent...
Scinai Immunotherapeutics announces $2.61M private placement
Scinai Immunotherapeutics (SCNI) announced that it has entered into a securities purchase agreement with an institutional life sciences investor, as well as with new and existing institutional and acc...
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs JE...
Scinai Immunotherapeutics completes strategic reorganization
Scinai Immunotherapeutics (SCNI) announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization. Building on its previ...
Scinai Immunotherapeutics targets $5M in CDMO revenue in 2026
Building on the new structure, the company’s 2026 objectives include: CDMO Platform: Scaling operations across both sites and expanding the customer base in the U.S. and Europe; Leveraging the Recipha...
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics a...
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed ...
Scinai Immunotherapeutics highlights expanded CDMO platform
Scinai Immunotherapeutics (SCNI) announced its participation in BIO-Europe Spring 2026, taking place March 23-25 in Lisbon, Portugal. During the conference, the team will meet with pharmaceutical and ...
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and th...
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Q...
Scinai Immunotherapeutics signs second amendment to PinCell option agreement
Scinai Immunotherapeutics (SCNI) announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under ...